-+ 0.00%
-+ 0.00%
-+ 0.00%

Amylyx Pharmaceuticals Selects AMX0318 As Novel Long-Acting GLP-1 Receptor Antagonist Development Candidate Through Gubra Collaboration

Benzinga·01/08/2026 12:14:59
Listen to the news
  • AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high solubility, and a favorable pharmacokinetic profile consistent with a long-acting peptide
     
  • IND-enabling studies expected to initiate in 2026 with an IND targeted for 2027, pending successful completion of IND-enabling studies